Group 1 - The core point of the news is that Jingtai Holdings (2228.HK) experienced a significant stock price increase of nearly 23%, reaching a new high of 8.1 HKD since February 25, following the announcement of a major collaboration with DoveTree [1] - Jingtai Technology announced on August 5 that it has completed a pipeline cooperation agreement with DoveTree, with a total order scale of approximately 470 billion HKD (59.9 billion USD) [1][3] - The agreement includes an initial payment of approximately 4 billion HKD (510 million USD) and potential further payments of about 3.85 billion HKD (490 million USD), along with milestone payments and sales shares amounting to approximately 462 billion HKD (58.9 billion USD) [3] Group 2 - The collaboration involves multiple preclinical stage large and small molecule innovative drug assets, with Jingtai Technology having the right to develop new drugs targeting specific DoveTree-designated targets [3] - DoveTree retains exclusive global development and commercialization rights for the related drugs [3] - This partnership sets a new record for order scale in the field of AI and robotics in new drug development [3]

Core Viewpoint - Jingtai Holdings (2228.HK) experienced a significant stock price increase of nearly 23%, reaching HKD 8.1, marking a new high since February 25. This surge is attributed to the announcement of a substantial collaboration with DoveTree, involving a total order scale of approximately HKD 470 billion (USD 59.9 billion) for pipeline cooperation [1] Group 1 - On August 5, Jingtai Technology announced the completion of a collaboration agreement with DoveTree, which includes an initial payment of approximately HKD 4 billion (USD 510 million) [1] - The agreement covers multiple preclinical stage large and small molecule innovative drug assets, with a focus on new drug development targeting various specified targets by DoveTree [1] - DoveTree will hold exclusive global development and commercialization rights for the related drugs, while Jingtai Technology is entitled to receive further payments of approximately HKD 3.85 billion (USD 490 million) and potential milestone payments and sales shares amounting to about HKD 462 billion (USD 58.9 billion) [1] Group 2 - This collaboration sets a new record in the field of AI and robotics for new drug development order scale [1]